EGFR and non-small cell lung carcinoma: SAVANNAH (NCT03778229), a Phase II study assessing the efficacy of osimertinib plus savolitinib in patients with EGFR-mutant, MET-amplified NSCLC who have progressed on osimertinib is investigating this combination further40.